Search

Background: Single-agent chemotherapy using methotrexate or actinomycin D is the first-line treatment for patients with low-risk gestational trophoblastic neoplasia. Various methotrexate-based and actinomycin D-based single-agent regimens can be used. However, there is insufficient evidence to determine the superior regimen. To guide doctors in selecting a single-agent chemotherapy regimen for patients with low-risk gestational trophoblastic neoplasia, we will compare two regimens. Methods: We will conduct a multicentre, randomized, prospective clinical trial. Selected low-risk gestational trophoblastic neoplasia patients (FIGO score 0–4) will be randomized 1:1 to a biweekly single-dose actinomycin D group or a multiday methotrexate therapy group. The actinomycin D group will receive IV pulse actinomycin D (1.25 mg/m2) every 14 days, and the methotrexate group will receive methotrexate (50 mg) intramuscularly on days 1, 3, 5, and 7 (4 doses per cycle) and leucovorin (15 mg) intramuscularly on days 2, 4, 6, and 8. This process will be repeated every 14 days. The primary endpoints will include the complete remission rate by single-agent therapy and the overall complete remission rate. The secondary endpoints will include the duration needed to achieve complete remission after single-agent chemotherapy, number of courses needed to achieve complete remission after single-agent chemotherapy, incidence and severity of adverse effects, effects on menstrual conditions and ovarian function based on the anti-Mullerian hormone level, and patient-reported quality of life. Discussion: Previous clinical trials comparing biweekly single-dose actinomycin D with multiday methotrexate therapy for treating low-risk gestational trophoblastic neoplasia patients failed to meet the expected case number. Through this multicentre study, the complete remission ratio and efficacy difference between biweekly single-dose actinomycin D and multiday methotrexate therapy will be obtained. This study will also provide the basis for formulating a preferred regimen for treating patients with low-risk gestational trophoblastic neoplasia. Trial registration: ClinicalTrials.gov: NCT04562558, Registered on 13 September 2020 (Protocol version 2020–9-24, version 1.0). [ABSTRACT FROM AUTHOR]

The study on neural systems is very hot, especially regarding modelling of fuzzy neural networks. The neuron models have been limited in interval [0,1] before. This paper studies the logic operators and neuron models of proposition object based on [a, b]. Any interval [a, b] is called a generalized interval. Firstly, authors provide the conception of proposition object, discussed on the radix space of universal logic. Secondly, using the NTS norms theories, this paper establishes the universal logic operation models on generalized interval [a, b]. Thirdly, the paper builds up a new uniform neuron model of "Not/And/Or/Average" on generalized interval [a, b]. As an instance, authors discuss the neuron models based on standard interval [0,1], which are continuously changeable with generalized correlation coefficient "h" and generalized self-correlation coefficient "k". This work offers important theories and models for neurons reasoning, make it more flexible because of the change of h, k and [a, b], and enlarge its study domain. [ABSTRACT FROM AUTHOR]